Mary Norine Walsh has become president of the American College of Cardiology during the Convocation Ceremony held in conjunction with the society’s 66th Annual Scientific Session (ACC; 17-19 March, Washington, DC, USA).
Researchers at Cleveland Clinic, Cleveland, USA, put five popular wrist-worn fitness trackers to the test to find out how accurately they gauge heart rate across several types of exercise and intensity levels.
Community coffee shops and cash machines might be ideal locations for public access to automated external defibrillators, according to new research published in Circulation.
As the Zika virus continues to spread globally, new evidence has emerged about the virus’s potentially detrimental effects on the heart, according to data presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC; 17-19 March, Washington, DC).
Late-breaking clinical research presented at the American College of Cardiology 66th Annual Scientific Sessions (ACC; 17-19 March, Washington, DC, USA) has shown treatment with Abbott’s CardioMEMS HF system to significantly reduce heart failure hospital admissions and improve the quality of life in patients with heart failure (NYHA Class III).
Patients with heart failure in the USA are more likely to be hospitalised and more likely to die during the colder winter months, according to two studies presented at the American College of Cardiology’s 66th Annual Scientific Session (ACC; 17-19 March, Washington, DC, USA). One study also shows the costs per hospitalisation for heart failure also increase during winter.
Data for a new drug that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) show that it is associated with a near 60% reduction in low-density lipoprotein (LDL) cholesterol and a significant reduction in cardiovascular events—making evolocumab (Repatha, Amgen) the first PCSK9 inhibitor to be associated with a reduction in hard cardiovascular outcomes. However, the drug was not associated with a reduction in cardiovascular mortality.
Two-year data from the ABSORB III study indicate that a bioresorbable vascular scaffold (Absorb, Abbott Vascular) is associated with a significantly higher rate of target lesion failure than is a permanent polymer everolimus-eluting stent (Xience, Abbott Vascular). However, a subanalysis of the study indicates that there are no significant differences in the rate of target lesion failure between Absorb and Xience if the scaffold is implanted in vessels ≥2.25mm.
Sung-Han Yoon (Cedars-Sinai Heart Institute, Los Angeles, USA) and others report in the Journal of the American College of Cardiology that all-cause mortality at two years in patients with bicuspid aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) is similar to that of patients with tricuspid aortic stenosis. When a first-generation device is used, the rate of adverse procedural events is significantly greater among bicuspid patients. However, when the newer-generation devices are used, the procedural outcomes were similar between bicuspid and tricuspid aortic stenosis.
Results from the SURTAVI clinical trial, which were presented today at the 2017 scientific sessions of the American College of Cardiology (17–19 March, Washington, DC, USA), indicate that transcatheter aortic valve implantation (TAVI) with self-expanding CoreValve device (Medtronic) is associated with a similar rate of all-cause mortality or disabling stroke as surgery in patients at intermediate risk at two years.
Vascular Graft Solutions has announced interim results of VEST III, a post-market randomised controlled study, to demonstrate the clinical significance of the venous external support (VEST) device—a kink resistant cobalt-chromium braided external stent applied on the outer surface of saphenous vein grafts when used in coronary artery bypass grafting (CABG). The interim results from the German and Austrian arms of the study, according to a press release, show there are no safety concerns around the application of VEST™ and excellent patency rate six months post-surgery.
Centurion Medical Products has launched its “smART” kit for radial arterial catheterisation onto the market. According to a press release, the kit positively impacts hospital arterial line placement protocols and budgets by decreasing procedure preparation time, eliminating wasted materials, and advancing innovation that may reduce infection risk.
Innovative Cardiovascular Solutions has announced the successful first European clinical cases using its Emblok embolic protection system in patients undergoing transcatheter aortic valve implantation (TAVI) procedures. The cases were performed by Azeem Latib and Matteo Montorfano under the direction of Antonio Colombo (all at San Raffaele Hospital, Milan, Italy).
A study published in European Heart Journal: Acute Cardiovascular Care indicates that delirium is associated with a five-fold increase in mortality in acute cardiac patients. Furthermore, it also shows that delirium was common and affected over half of acute cardiac patients aged 85 years and older.
A study, published in the Journal of Interventional Cardiology, indicates that females, bleeding, and blood transfusions—among others—are associated with lower odds for an early discharge after transcatheter aortic valve implantation (TAVI). However, the transfemoral approach and prior aortic valvuloplasty were associated with increased likelihood for early discharge.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos